DSC_1930

Dr. Buel "Dan" Rodgers

Founder/Chief Executive Officer

Dr. Rodgers has over 23 years research experience in the control of skeletal and cardiac muscle development. He received his Ph.D. from the University of California, Berkeley and has won numerous awards for research, teaching and mentorship. He held faculty positions in Pediatric Endocrinology at the Johns Hopkins University School of Medicine and also in Molecular Biosciences at Washington State University where he founded and directed the Washington Center for Muscle Biology.

Management

  • Chief Business Officer: Dr. Heather Webb Hsu
    17 years as an industry scientist, team manager & business developer; holds 17 patents.
  • Advisor, Business Development: Jade Brown, MBA
    Principle of Jade Brown consulting: 27 years in the field, 17 in senior-level leadership.
  • Director of Preclinical Development: Dr. Peter Korytko
    President of Preclinical GPS; 17 years' industry experience advancing INDs into clinical trials.
  • Director of Regulatory Affairs: Jeff Fellows
    32 years' industry experience working with the FDA and other health authorities.

Science Advisory Board

AAVogen is advised by highly respected and extremely well established leaders in the fields of gene therapy, muscle disease and molecular biology. This includes experts in viral gene delivery systems, muscular dystrophies, cancer cachexia, cardiac disease and regenerative medicine. Such expertise complements that of AAVogen's leadership and partners, which together forms a muscle gene therapy dream team.

Gregorevic1

Paul Gregorevic, Ph.D.

Associate Professor of Physiology, Deputy Director of the Center for Muscle Research, University of Melbourne and co-discoverer of AVGN7.

 

GuttridgeDenis

Denis Guttridge, Ph.D.

Professor and Director, Darby Children's Research Institute and Associate Director of Translational Sciences, Hollings Cancer Center, Medical University of South Carolina.

 

jeff

Jeff Chamberlain, Ph.D.

Endowed Professor at the University of Washington and Director of the Seattle Wellstone Muscular Dystrophy Cooperative Research Center.

 

Lawson Macartney_789A0062_pp

Lawson Macartney, D.V.M./Ph.D.

Expert in commercialization and manufacturing of AAV-based gene therapeutics.  28 years pharma experience and senior leadership (e.g. CEO, Sr. VP) at Shire, AstraZeneca, GSK and Ambrx.

image001

Charles Murry, M.D.

Endowed Professor and Director of the Institute for Regenerative Medicine as well as the Center for Cardiovascular Biology at the University of Washington.

 

qtq80-yCVIMt

To be named

An expert in limb girdle muscular dystrophy will soon be appointed to the Science Advisory Board.

Board of Directors

AAVogen is currently pursuing Series-A financing and is in the process of establishing a Board of Directors.  For more information on investing in AAVogen, please click the link to the right.